

Mississippi Division Of Medicaid
Provider Notice of Preferred Drug List Changes
P&T Meeting Date: February 13, 2024
PDL Changes Effective Date: April 1, 2024



The following changes will be made to the Preferred Drug List (PDL), effective April 1, 2024, pending approval by the P&T Committee, DOM, and DOM's Executive Director.

NEW PREFERRED DRUGS	
THERAPEUTIC CLASS	RECOMMENDED for PREFERRED STATUS
Antineoplastics – Selected Systemic Enzyme Inhibitors	Rozlytrek (entrectinib) Pellet Pack
Antineoplastics – Selected Systemic Enzyme Inhibitors	Xalkori (crizotinib) Oral Pellets
Opiate Dependence Treatments - Treatment	Kloxxado (naloxone)
Opiate Dependence Treatments - Treatment	Opvee (nalmefene)
Ulcerative Colitis and Crohn's Agents	Pentasa (mesalamine)
Ulcerative Colitis and Crohn's Agents	Lialda (mesalamine)
Ulcerative Colitis and Crohn's Agents	Apriso (mesalamine)
Ulcerative Colitis and Crohn's Agents	Uceris (budesonide)

NEW NON-PREFERRED DRUGS	
THERAPEUTIC CLASS	RECOMMENDED for NON-PREFERRED STATUS
Acne Agents - Combination Drugs/ Others	Cabtreo (clindamycin phosphate, adapalene, and benzoyl peroxide)
Antibiotics (GI) & Related Agents	Likmez (metronidazole) oral suspension
Antibiotics (GI) & Related Agents	metronidazole capsules
Anticonvulsants – Adjuvants	Motpoly XR (lacosamide)
Antidepressants, Other	Zurzuvae (zuranolone)
Antineoplastics – Selected Systemic Enzyme Inhibitors	Augtyro (repotrectinib)
Antineoplastics – Selected Systemic Enzyme Inhibitors	Fruzaqla (fruquintinib)
Antineoplastics – Selected Systemic Enzyme Inhibitors	Ojjaara (mometinib)

Mississippi Division Of Medicaid
Provider Notice of Preferred Drug List Changes
P&T Meeting Date: February 13, 2024
PDL Changes Effective Date: April 1, 2024



NEW NON-PREFERRED DRUGS	
THERAPEUTIC CLASS	RECOMMENDED for NON-PREFERRED STATUS
Antineoplastics – Selected Systemic Enzyme Inhibitors	Truqap (capivasertib)
Antipsychotics- Injectable, Atypicals	Rykindo (risperidone)
Bronchodilators, Beta Agonist: Inhalers, Short-Acting	Airsupra (albuterol and budesonide)
Cytokine & CAM Antagonists	Bimzelx (bimekizumab-bkzx)
Cytokine & CAM Antagonists	Omvo (mirikizumab-mrkz)
Cytokine & CAM Antagonists	Cosentyx 125mg/5 ml single use vial (secukinumab)
Cytokine & CAM Antagonists	Entyvio (vedolizumab, subcutaneous)
Cytokine & CAM Antagonists	Jylamvo (methotrexate)
Erythropoiesis Stimulating Proteins	Jesduvroq (daprodustat)
GI Ulcer Therapies - Other	Voquezna (vonoprazan)
H. Pylori Combination Treatments	Voquezna Dual Pak (vonoprazan tablets, amoxicillin capsules)
H. Pylori Combination Treatments	Voquezna Triple Pak (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets)
Muscular Dystrophy Agents	Elevidys (delandistrogene moxeparvovec-rokl)
Ophthalmic, Dry Eye Agents	Veyve (cyclosporine ophthalmic solution)
Phosphate Binders	Xphozah (tenapanor)
Ulcerative Colitis and Crohn's Agents	Velsipity (etrasimod)